Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the FirmNEW YORK, NY - June 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law ViolationsNEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law ViolationsNEW YORK, NY - June 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsNEW YORK, NY - June 16, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)NEW YORK, NY - June 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law ViolationsNEW YORK, NY - June 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsNEW YORK, NY - June 8, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact Kaplan Fox Regarding an Investigation Into Possible Securities Law ViolationsNEW YORK, NY - June 5, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
Shareholders of Fulcrum Therapeutics, Inc. (
NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (SCD) ―
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
